UNSPSC 51171826: Alepride

This classification denotes an antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6G1M06TPO. European Medicines Agency schedules Alepride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05309MIG. Alepride generally arises in the molecular formula C22H30CLN3O2.

UNSPSC 51171826 Alepride, a Commodity code, encompasses pharmaceutical and laboratory testing services that state and local governments procure for criminal justice supervision, public health programs, and employee benefit management. Recent solicitations reveal state and local buyers purchasing offender drug testing with specimen collection and laboratory analysis; direct-to-manufacturer prescription fulfillment programs; and generic pharmaceuticals with over-the-counter products distributed through authorized wholesalers. Issuing bodies include county community supervision departments (Collin County, Texas), state health and human services commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances administering regional procurement (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon).

Recent activity concentrates in Texas and the Upper Midwest. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, soliciting offender specimen collection and drug testing services with proposals due July 23, 2026, covering staffing at two collection sites, immunoassay screening with LC/MS/MS or GC/MS confirmation, and interactive voice response notification, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, with three optional one-year renewals. The Texas Health and Human Services Commission issued an exploratory RFI on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent split among administrative compliance, EDI capability, and administrative fee agreement; awarded vendors become effective July 1, 2026.